# Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

> **NCT01053936** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 129 (actual)

## Conditions studied

- Renal Insufficiency, Chronic
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Bardoxolone methyl (amorphous dispersion)

## Key facts

- **NCT ID:** NCT01053936
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-31
- **Primary completion:** 2010-12-31
- **Final completion:** 2011-02-28
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01053936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01053936, "Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01053936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*